AU2001290706A1 - Antisense modulation of clusterin expression - Google Patents
Antisense modulation of clusterin expressionInfo
- Publication number
- AU2001290706A1 AU2001290706A1 AU2001290706A AU9070601A AU2001290706A1 AU 2001290706 A1 AU2001290706 A1 AU 2001290706A1 AU 2001290706 A AU2001290706 A AU 2001290706A AU 9070601 A AU9070601 A AU 9070601A AU 2001290706 A1 AU2001290706 A1 AU 2001290706A1
- Authority
- AU
- Australia
- Prior art keywords
- clusterin
- expression
- antisense modulation
- clusterin expression
- antisense
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000003780 Clusterin Human genes 0.000 title abstract 5
- 108090000197 Clusterin Proteins 0.000 title abstract 5
- 230000000692 anti-sense effect Effects 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 abstract 1
- 239000000074 antisense oligonucleotide Substances 0.000 abstract 1
- 238000012230 antisense oligonucleotides Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09659791 | 2000-09-11 | ||
US09/659,791 US6383808B1 (en) | 2000-09-11 | 2000-09-11 | Antisense inhibition of clusterin expression |
PCT/US2001/028235 WO2002022635A1 (fr) | 2000-09-11 | 2001-09-10 | Modulation antisens de l'expression de la clusterine |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001290706A1 true AU2001290706A1 (en) | 2002-03-26 |
Family
ID=24646855
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001290706A Abandoned AU2001290706A1 (en) | 2000-09-11 | 2001-09-10 | Antisense modulation of clusterin expression |
Country Status (7)
Country | Link |
---|---|
US (2) | US6383808B1 (fr) |
EP (1) | EP1325019B1 (fr) |
JP (3) | JP4397585B2 (fr) |
AT (1) | ATE496127T1 (fr) |
AU (1) | AU2001290706A1 (fr) |
DE (1) | DE60143901D1 (fr) |
WO (1) | WO2002022635A1 (fr) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040121973A1 (en) * | 2002-02-05 | 2004-06-24 | Monia Brett P | Antisense modulation of protein phosphatase 2 Catalytic subunit alpha expression |
US6444650B1 (en) * | 1996-10-01 | 2002-09-03 | Geron Corporation | Antisense compositions for detecting and inhibiting telomerase reverse transcriptase |
HU227190B1 (en) * | 1999-02-26 | 2010-10-28 | Univ British Columbia | Trpm-2 antisense therapy |
US6900187B2 (en) * | 1999-02-26 | 2005-05-31 | The University Of British Columbia | TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications |
US7569551B2 (en) | 2000-02-25 | 2009-08-04 | The University Of British Columbia | Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides |
US7199102B2 (en) * | 2000-08-24 | 2007-04-03 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
US7148197B2 (en) * | 2000-08-24 | 2006-12-12 | The Regents Of The University Of California | Orally administered small peptides synergize statin activity |
US8568766B2 (en) | 2000-08-24 | 2013-10-29 | Gattadahalli M. Anantharamaiah | Peptides and peptide mimetics to treat pathologies associated with eye disease |
US7723303B2 (en) * | 2000-08-24 | 2010-05-25 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
US7407943B2 (en) * | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
NZ533126A (en) | 2002-01-17 | 2006-04-28 | Univ British Columbia | Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same |
US20040102401A1 (en) * | 2002-11-22 | 2004-05-27 | Isis Pharmaceuticals Inc. | Modulation of jagged 1 expression |
WO2004003201A2 (fr) * | 2002-07-01 | 2004-01-08 | Pharmacia Corporation | Modulation antisens de l'expression de lrh1 |
US7285541B2 (en) | 2002-08-21 | 2007-10-23 | The University Of British Columbia | Treatment of melanoma by reduction in clusterin levels |
KR101212512B1 (ko) * | 2002-08-21 | 2012-12-26 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 암-관련 단백질을 표적으로 하는 알엔에이아이 프로브 |
WO2004092378A2 (fr) * | 2003-04-18 | 2004-10-28 | The University Of British Columbia | Technique de traitement de pathologies angiogeniques cancereuses |
JP2007523839A (ja) * | 2003-04-18 | 2007-08-23 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | 血管新生性障害の治療法 |
US7825235B2 (en) * | 2003-08-18 | 2010-11-02 | Isis Pharmaceuticals, Inc. | Modulation of diacylglycerol acyltransferase 2 expression |
US20050164271A1 (en) * | 2004-01-20 | 2005-07-28 | Sanjay Bhanot | Modulation of glucocorticoid receptor expression |
WO2005067957A2 (fr) * | 2004-01-20 | 2005-07-28 | Develogen Aktiengesellschaft | Utilisation d'un produit proteique dg47 pour la prevention et le traitement de troubles metaboliques |
WO2005094899A1 (fr) | 2004-04-02 | 2005-10-13 | The University Of British Columbia | Traitement de cancers par un antisens anti-clusterine |
JP2008513479A (ja) * | 2004-09-16 | 2008-05-01 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | アテローム性動脈硬化症および他の病理を改善するためのg型ペプチドおよび他の薬剤 |
ITBZ20040048A1 (it) * | 2004-10-06 | 2005-01-06 | Genprofiler | Metodo per l'identificazione della trasformazione neoplastica, con particolare riferimento al cancro prostatico |
US20080014198A1 (en) * | 2004-11-23 | 2008-01-17 | The University Of British Columbia | Treatment of Cancer With a Combination of an Agent that Perturbs the EGF Signaling Pathway and an Oligonucleotide that Reduces Clusterin Levels |
KR20070089996A (ko) | 2004-12-06 | 2007-09-04 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 세동맥의 구조 및 기능의 개선 방법 |
SG173373A1 (en) * | 2005-04-29 | 2011-08-29 | The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
US20080293639A1 (en) * | 2005-04-29 | 2008-11-27 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
AU2006291990B2 (en) | 2005-09-13 | 2012-05-31 | National Research Council Of Canada | Methods and compositions for modulating tumor cell activity |
JP2010522245A (ja) | 2007-03-24 | 2010-07-01 | ゲンザイム コーポレイション | ヒトアポリポタンパク質bと相補的なアンチセンスオリゴヌクレオチドの投与 |
AU2008296487A1 (en) | 2007-08-28 | 2009-03-12 | The Uab Research Foundation | Synthetic apolipoprotein E mimicking polypeptides and methods of use |
AU2008296478B9 (en) | 2007-08-28 | 2015-03-19 | The Uab Research Foundation | Synthetic apolipoprotein E mimicking polypeptides and methods of use |
WO2009067243A2 (fr) * | 2007-11-20 | 2009-05-28 | Isis Pharmaceuticals Inc. | Modulation de l'expression de cd40 |
CA2744987C (fr) | 2008-12-02 | 2018-01-16 | Chiralgen, Ltd. | Procede pour la synthese d'acides nucleiques modifies par des atomes de phosphore |
BR112012000828A8 (pt) | 2009-07-06 | 2017-10-10 | Ontorii Inc | Novas pró-drogas de ácido nucleico e métodos de uso das mesmas |
CN102666585B (zh) | 2009-11-24 | 2015-02-18 | 阿莱斯亚生物疗法股份有限公司 | 抗簇蛋白抗体和抗原结合片段及其减小肿瘤体积的用途 |
WO2012039448A1 (fr) | 2010-09-24 | 2012-03-29 | 株式会社キラルジェン | Groupe auxiliaire asymétrique |
CA2826043A1 (fr) | 2011-02-03 | 2012-08-09 | Mirna Therapeutics, Inc. | Mimetiques synthetiques de mir-124 |
AU2012212023B9 (en) | 2011-02-03 | 2017-01-12 | Mirna Therapeutics, Inc. | Synthetic mimics of miR-34 |
KR20140038388A (ko) | 2011-03-15 | 2014-03-28 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 전립선암의 치료를 위한 항-클러스테린 올리고뉴클레오타이드와 hsp90 저해제의 병용 |
US9605019B2 (en) | 2011-07-19 | 2017-03-28 | Wave Life Sciences Ltd. | Methods for the synthesis of functionalized nucleic acids |
DK2756080T3 (da) | 2011-09-14 | 2019-05-20 | Translate Bio Ma Inc | Multimeriske oligonukleotidforbindelser |
WO2013123588A1 (fr) | 2012-02-22 | 2013-08-29 | Alethia Biotherapeutics Inc. | Utilisation conjointe d'un inhibiteur de clusterine et d'un inhibiteur d'egfr pour traiter le cancer |
CA2873779A1 (fr) | 2012-05-16 | 2013-11-21 | Rana Therapeutics Inc. | Compositions et methodes pour moduler l'expression de mecp2 |
US10837014B2 (en) | 2012-05-16 | 2020-11-17 | Translate Bio Ma, Inc. | Compositions and methods for modulating SMN gene family expression |
AU2013288048A1 (en) | 2012-07-13 | 2015-01-22 | Wave Life Sciences Ltd. | Asymmetric auxiliary group |
KR101835401B1 (ko) | 2012-07-13 | 2018-03-08 | 신 니뽄 바이오메디칼 라보라토리즈, 엘티디. | 키랄 핵산 어쥬번트 |
KR20220139425A (ko) | 2012-07-13 | 2022-10-14 | 웨이브 라이프 사이언시스 리미티드 | 키랄 제어 |
US20150247141A1 (en) | 2012-09-14 | 2015-09-03 | Rana Therapeutics, Inc. | Multimeric oligonucleotide compounds |
US10322173B2 (en) | 2014-01-15 | 2019-06-18 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
WO2015108048A1 (fr) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | Adjuvant d'acide nucléique chiral ayant un effet antitumoral et agent antitumoral |
EP3095461A4 (fr) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Adjuvant d'acide nucléique chiral possédant une activité d'induction d'immunité, et activateur d'induction d'immunité |
PT3094728T (pt) | 2014-01-16 | 2022-05-19 | Wave Life Sciences Ltd | Desenho quiral |
BR112017001860A2 (pt) | 2014-07-31 | 2018-02-27 | Uab Research Foundation | peptídeo sintético, composição farmacêutica, métodos, regime de dosagem, e, anticorpo monoclonal |
EP3256592A4 (fr) * | 2015-02-13 | 2018-09-12 | Translate Bio Ma, Inc. | Compositions et procédés de modulation de l'arn |
US10758558B2 (en) | 2015-02-13 | 2020-09-01 | Translate Bio Ma, Inc. | Hybrid oligonucleotides and uses thereof |
US20180142236A1 (en) * | 2015-05-15 | 2018-05-24 | Ge Healthcare Dharmacon, Inc. | Synthetic single guide rna for cas9-mediated gene editing |
AU2016294347B2 (en) | 2015-07-10 | 2022-07-28 | Ionis Pharmaceuticals, Inc. | Modulators of diacyglycerol acyltransferase 2 (DGAT2) |
FR3069156B1 (fr) * | 2017-07-21 | 2019-08-09 | Universite de Bordeaux | Clusterine pour son utilisation dans le traitement des micro-angiopathies thrombotiques |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3687808A (en) | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
US5405938A (en) | 1989-12-20 | 1995-04-11 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
US5216141A (en) | 1988-06-06 | 1993-06-01 | Benner Steven A | Oligonucleotide analogs containing sulfur linkages |
US5264562A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences, Inc. | Oligonucleotide analogs with novel linkages |
US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
US5470967A (en) | 1990-04-10 | 1995-11-28 | The Dupont Merck Pharmaceutical Company | Oligonucleotide analogs with sulfamate linkages |
US5610289A (en) | 1990-07-27 | 1997-03-11 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogues |
US5541307A (en) | 1990-07-27 | 1996-07-30 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs and solid phase synthesis thereof |
US5602240A (en) | 1990-07-27 | 1997-02-11 | Ciba Geigy Ag. | Backbone modified oligonucleotide analogs |
US5489677A (en) | 1990-07-27 | 1996-02-06 | Isis Pharmaceuticals, Inc. | Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms |
US5214134A (en) | 1990-09-12 | 1993-05-25 | Sterling Winthrop Inc. | Process of linking nucleosides with a siloxane bridge |
US5561225A (en) | 1990-09-19 | 1996-10-01 | Southern Research Institute | Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages |
EP0549686A4 (en) | 1990-09-20 | 1995-01-18 | Gilead Sciences Inc | Modified internucleoside linkages |
FR2692265B1 (fr) | 1992-05-25 | 1996-11-08 | Centre Nat Rech Scient | Composes biologiquement actifs de type phosphotriesters. |
US5434257A (en) | 1992-06-01 | 1995-07-18 | Gilead Sciences, Inc. | Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages |
GB9304618D0 (en) | 1993-03-06 | 1993-04-21 | Ciba Geigy Ag | Chemical compounds |
FR2705099B1 (fr) | 1993-05-12 | 1995-08-04 | Centre Nat Rech Scient | Oligonucléotides phosphorothioates triesters et procédé de préparation. |
US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
AUPM301293A0 (en) | 1993-12-17 | 1994-01-20 | University Of Melbourne, The | Methods and reagents for sperm analysis |
US5695995A (en) * | 1994-05-06 | 1997-12-09 | Fred Hutchinson Cancer Research Center | Neurogenic differentiation (neurod) genes |
US5786213A (en) * | 1996-04-18 | 1998-07-28 | Board Of Regents, The University Of Texas System | Inhibition of endogenous gastrin expression for treatment of colorectal cancer |
US5739310A (en) * | 1996-04-23 | 1998-04-14 | Fred Hutchinson Cancer Research Center | Ribosomes as vectors for RNA |
US5945290A (en) * | 1998-09-18 | 1999-08-31 | Isis Pharmaceuticals, Inc. | Antisense modulation of RhoA expression |
US5959097A (en) * | 1998-11-20 | 1999-09-28 | Isis Pharmaceuticals, Inc. | Antisense modulation of MEK2 expression |
AU3116800A (en) * | 1998-12-11 | 2000-06-26 | Research Foundation Of The State University Of New York, The | Compositions and methods for altering cell migration |
US5958773A (en) * | 1998-12-17 | 1999-09-28 | Isis Pharmaceuticals Inc. | Antisense modulation of AKT-1 expression |
US5948680A (en) * | 1998-12-17 | 1999-09-07 | Isis Pharmaceuticals Inc. | Antisense inhibition of Elk-1 expression |
HU227190B1 (en) | 1999-02-26 | 2010-10-28 | Univ British Columbia | Trpm-2 antisense therapy |
US5998148A (en) * | 1999-04-08 | 1999-12-07 | Isis Pharmaceuticals Inc. | Antisense modulation of microtubule-associated protein 4 expression |
-
2000
- 2000-09-11 US US09/659,791 patent/US6383808B1/en not_active Expired - Lifetime
-
2001
- 2001-09-10 WO PCT/US2001/028235 patent/WO2002022635A1/fr active Application Filing
- 2001-09-10 AT AT01970728T patent/ATE496127T1/de not_active IP Right Cessation
- 2001-09-10 EP EP01970728A patent/EP1325019B1/fr not_active Expired - Lifetime
- 2001-09-10 AU AU2001290706A patent/AU2001290706A1/en not_active Abandoned
- 2001-09-10 US US10/380,124 patent/US20040053874A1/en not_active Abandoned
- 2001-09-10 JP JP2002526886A patent/JP4397585B2/ja not_active Expired - Fee Related
- 2001-09-10 DE DE60143901T patent/DE60143901D1/de not_active Expired - Lifetime
-
2009
- 2009-08-21 JP JP2009191924A patent/JP2010043086A/ja active Pending
-
2013
- 2013-07-29 JP JP2013156811A patent/JP2014027936A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP4397585B2 (ja) | 2010-01-13 |
DE60143901D1 (de) | 2011-03-03 |
US6383808B1 (en) | 2002-05-07 |
JP2010043086A (ja) | 2010-02-25 |
ATE496127T1 (de) | 2011-02-15 |
JP2014027936A (ja) | 2014-02-13 |
JP2004513626A (ja) | 2004-05-13 |
US20040053874A1 (en) | 2004-03-18 |
WO2002022635A1 (fr) | 2002-03-21 |
EP1325019A4 (fr) | 2006-09-20 |
EP1325019B1 (fr) | 2011-01-19 |
EP1325019A1 (fr) | 2003-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001290706A1 (en) | Antisense modulation of clusterin expression | |
WO2002036743A3 (fr) | Modulation antisens de l'expression de calreticuline | |
WO2003011887A3 (fr) | Modulation antisens de l'expression de l'apolipoproteine b | |
WO2002092772A3 (fr) | Modulation antisens de l'expression de ptp1b | |
EP1131465A4 (fr) | Modulation antisens de l'expression de l'interleukine 15 | |
AU2001226246A1 (en) | Antisense inhibition of ptp1b expression | |
EP1248794A4 (fr) | Modulation antisens de l'expression de la proteine smad7 | |
WO2004044181A3 (fr) | Modulation antisens de l'expression d'apolipoproteine b | |
WO2002010378A3 (fr) | Modulation antisens de l'expression de ptp1b | |
WO2003097662A8 (fr) | Modulation antisens de l'expression de l'apolipoproteine b | |
WO2003046132A3 (fr) | Modulation antisens de l'expression du myd88 | |
EP1131332A4 (fr) | Modulation antisens de l'expression de la kappa b kinase beta inhibitrice | |
EP1131107A4 (fr) | Modulation antisens de l'expression de kappa b kinase alpha inhibitrice | |
WO2001029175A3 (fr) | Modulation antisens de l'expression de fra-1 | |
WO2003053341A3 (fr) | Modulation antisens de l'expression de ship-1 | |
WO2002095053A3 (fr) | Modulation antisens de l'expression des src-c | |
WO2001083513A3 (fr) | Modulation antisens de l'inhibiteur de l'expression de la fixation 1 a l'adn | |
WO2002050248A3 (fr) | Modulation antisens de l'expression de l'hepsine | |
WO2003052062A3 (fr) | Modulation antisens de l'expression de cd36l1 | |
WO2003027229A3 (fr) | Modulation antisens de l'expression de rip2 | |
WO2000061786A3 (fr) | Modulation antisens de l'expression de pdk-1 | |
WO2002041836A3 (fr) | Modulation antisens de l'expression de src-1 | |
WO2003031576A3 (fr) | Modulation antisens de l'expression de l'inhibiteur kappa b kinase-gamma | |
WO2002055535A3 (fr) | Modulation antisens de l'expression de la cytohesine-1 | |
WO2002042425A3 (fr) | Modulation antisens de l'expression mp-1 |